Rs867228 in FPR1 accelerates the manifestation of luminal B breast cancer

The loss-of-function mutation in the Formyl peptide receptor-1 (FPR1) gene, called rs867228, affects approximately one-third of the population across continents. A bioinformatics study found that this mutation accelerates the age of diagnosis of specific carcinomas, including luminal B breast cancer, by 4.9 years. The study was validated on 215 patients with metastatic luminal B mammary carcinomas, confirming that rs867228 accelerated the age of diagnosis by 6.3 years. The authors suggest that screening for this mutation may be useful in breast cancer screening campaigns to start examinations at a younger age.